You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
15 November 2021
Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021
15 September 2021
Antengene Selected as a Constituent of the FTSE Global Equity Index Series
18 May 2021
Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)
29 April 2021
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
15 March 2021
Antengene Included in the Shenzhen-Hong Kong Stock Connect
1 March 2021
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Index-es Including the Hang Seng Composite Index
28 January 2021
Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM
21 December 2020
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
7 December 2020
Antengene Announces Acceptance of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
3 December 2020
Antengene Submits NDAs for XPOVIO(R) (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL
26 November 2020
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
9 November 2020
Antengene Corporation Limited Announces Proposed Listing on the Main Board of SEHK Premier Integrated Platform in APAC to Develop Innovative Therapies for Oncology Near-term Commercialization Launch Prospects of Core Products Offer price between HK$15.80 and HK$18.08 per share
15 October 2020
Antengene’s New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer